

# Definitions in Hemophilia

Thrombosis and Haemostasis

85, 560-560

DOI: [10.1055/s-0037-1615621](https://doi.org/10.1055/s-0037-1615621)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics of Coagulation Factors. <i>Clinical Pharmacokinetics</i> , 2001, 40, 815-832.	1.6	143
2	Unexpected Bleeding Disorders. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 306-321.	0.9	10
3	Inhibitors: resolving diagnostic and therapeutic dilemmas. <i>Haemophilia</i> , 2002, 8, 280-287.	1.0	130
4	Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. <i>Haemophilia</i> , 2002, 8, 768-775.	1.0	40
5	Factor VIIa: Use in Patients With Hemophilia. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2003, 5, 15-19.	0.2	1
6	Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine <sup>®</sup> ) in haemophilia B. <i>Haemophilia</i> , 2003, 9, 164-172.	1.0	34
7	Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. <i>Haemophilia</i> , 2003, 9, 348-352.	1.0	60
8	Haemophilias A and B. <i>Lancet, The</i> , 2003, 361, 1801-1809.	6.3	650
10	Inhibitors in congenital coagulation disorders. <i>British Journal of Haematology</i> , 2004, 127, 379-391.	1.2	129
11	The impact of unaware carriership on the clinical presentation of haemophilia. <i>Haemophilia</i> , 2004, 10, 560-564.	1.0	43
12	Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 102-110.	1.9	162
13	Enhanced factor VIII activity measurements using ROTEG and factor VIII <sup>-/-</sup> mice whole blood. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2274-2275.	1.9	5
14	Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand. <i>Haemophilia</i> , 2004, 10, 18-26.	1.0	19
15	Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody. <i>American Journal of Hematology</i> , 2004, 77, 346-350.	2.0	12
16	Blood Products for Hemophilia. <i>BioDrugs</i> , 2004, 18, 225-234.	2.2	12
17	Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors. , 2004, , CD004449.		1
18	Inhibitors in hemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 109-124.	0.5	75
19	Creation of a mouse expressing defective human factor IX. <i>Blood</i> , 2004, 104, 1733-1739.	0.6	45

#	ARTICLE	IF	CITATIONS
20	Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 597-605.	0.5	49
21	Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 585-596.	0.5	17
22	Inhibitors to Factor VIII”Epidemiology and Treatment. , 0, , 64-70.		15
23	The molecular analysis of haemophilia A: a guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network. <i>Haemophilia</i> , 2005, 11, 387-397.	1.0	66
24	The molecular analysis of haemophilia B: a guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network. <i>Haemophilia</i> , 2005, 11, 398-404.	1.0	19
25	Inherited coagulation disorders in the northwestern region of Iran. <i>Haemophilia</i> , 2005, 11, 424-426.	1.0	11
26	Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. <i>Haemophilia</i> , 2005, 11, 611-619.	1.0	82
27	Rehabilitation of a Hemophiliac With Implants: A Medical Perspective and Case Report. <i>Journal of Oral and Maxillofacial Surgery</i> , 2005, 63, 592-597.	0.5	21
28	Inhibitors of Factor VIII: Treatment of Acute Bleeds. , 0, , 80-85.		8
29	Angeborene plasmatische GerinnungsstÄrungen. , 2005, , 1195-1211.		1
30	Hemophilia: A Practical Approach to Genetic Testing. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1485-1499.	1.4	26
31	Haemophilia B: Christmas disease. Expert Opinion on Pharmacotherapy, 2005, 6, 1517-1524.	0.9	38
32	Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura. <i>Pharmacoeconomics Italian Research Articles</i> , 2006, 8, 33-44.	0.2	1
33	Current Opinion on Inhibitor Treatment Options. <i>Seminars in Hematology</i> , 2006, 43, S8-S13.	1.8	18
34	Management of factor VIII inhibitors. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 51-66.	0.7	18
35	Systemic Disorders in Infants and Children. , 2006, , 1032-1109.		1
36	Do hemophilia carriers bleed? Yes.. <i>Blood</i> , 2006, 108, 6-6.	0.6	12
37	Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. <i>Blood</i> , 2006, 107, 46-51.	0.6	278

#	ARTICLE	IF	CITATIONS
38	Bleeding in carriers of hemophilia. <i>Blood</i> , 2006, 108, 52-56.	0.6	300
39	Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. <i>Blood</i> , 2006, 107, 3167-3172.	0.6	241
40	Microvascular Free Tissue Transfer in Patients with Hematological Disorders. <i>Plastic and Reconstructive Surgery</i> , 2006, 118, 936-944.	0.7	15
43	Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A. <i>Haemophilia</i> , 2006, 12, 605-614.	1.0	23
44	Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. <i>Haemophilia</i> , 2006, 12, 8-14.	1.0	129
45	The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. <i>Haemophilia</i> , 2006, 12, 4-13.	1.0	29
46	Commentary: 'Switching between full-length and B-domain deleted Factor VIII and the risk of inhibitors'. <i>Haemophilia</i> , 2006, 12, 561-562.	1.0	0
47	Management of Factor VIII Inhibitors. <i>International Journal of Hematology</i> , 2006, 83, 119-125.	0.7	27
48	Characterization of Factor VIII Inhibitors. <i>International Journal of Hematology</i> , 2006, 83, 109-118.	0.7	12
49	Coagulation Defects. <i>Anesthesiology Clinics</i> , 2006, 24, 549-578.	1.4	15
50	Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution. <i>Human Mutation</i> , 2006, 27, 676-685.	1.1	31
51	The Role of Immunomodulation in the Management of Factor VIII Inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 421-425.	0.9	14
52	Genetics of Coagulation: Considerations for Cardiac Surgery. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2006, 10, 297-313.	0.4	5
53	Hemophilia A and B. , 0, , 583-597.		0
54	Hematologic Problems in Psychosomatic Medicine. <i>Psychiatric Clinics of North America</i> , 2007, 30, 739-759.	0.7	16
55	Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. <i>Haemophilia</i> , 2007, 13, 51-56.	1.0	45
56	International workshop on immune tolerance induction: consensus recommendations. <i>Haemophilia</i> , 2007, 13, 1-22.	1.0	228
57	European Study on Orthopaedic Status of haemophilia patients with inhibitors. <i>Haemophilia</i> , 2007, 13, 606-612.	1.0	192

#	ARTICLE	IF	CITATIONS
58	Optimizing outcomes for patients with severe haemophilia A. <i>Haemophilia</i> , 2007, 13, 1-16.	1.0	235
59	Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B. <i>Haemophilia</i> , 2007, 14, 071115150757002-???.	1.0	10
60	VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice. <i>Haemophilia</i> , 2007, 13, 69-72.	1.0	15
61	Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1383-1390.	1.9	134
62	Amelioration of clinical severity of similar mutations severe factor IX deficiency by coinherited thrombophilia. <i>European Journal of Haematology</i> , 2007, 80, 071119184130004-???.	1.1	0
63	Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A. <i>Journal of Human Genetics</i> , 2008, 53, 275-284.	1.1	44
64	European principles of haemophilia care. <i>Haemophilia</i> , 2008, 14, 361-374.	1.0	191
65	<i>In vivo</i> models of haemophilia – status on current knowledge of clinical phenotypes and therapeutic interventions. <i>Haemophilia</i> , 2008, 14, 248-259.	1.0	25
66	The spectrum of the <i>factor 8</i> ( <i>F8</i> ) defects in Taiwanese patients with haemophilia A. <i>Haemophilia</i> , 2008, 14, 787-795.	1.0	20
67	Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. <i>Haemophilia</i> , 2008, 14, 196-201.	1.0	34
68	One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. <i>Haemophilia</i> , 2008, 14, 1049-1054.	1.0	60
69	A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate <sup>®</sup> /Humate <sup>®</sup> : History and clinical performance. <i>European Journal of Haematology</i> , 2008, 80, 3-35.	1.1	42
70	Chapter 45 Hematological diseases and stroke. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 93, 887-934.	1.0	1
71	Access to special care dentistry, part 5. Safety. <i>British Dental Journal</i> , 2008, 205, 177-190.	0.3	30
72	Coagulopat?as cong?nitas. <i>Medicine</i> , 2008, 10, 1483-1487.	0.0	0
73	Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1885-1896.	1.4	4
74	Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites. <i>Blood</i> , 2008, 111, 3468-3478.	0.6	16
75	Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. <i>Blood</i> , 2008, 112, 2713-2721.	0.6	100

#	ARTICLE	IF	CITATIONS
76	Determining the adequate number of internal quality control levels: the example of coagulation factor VIII assay. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 433-437.	0.5	6
77	A consensus statement on the management of pregnancy and delivery in women who are carriers of or have bleeding disorders. <i>Medical Journal of Australia</i> , 2009, 191, 460-463.	0.8	26
78	Inhibitors of Factor VIII in Black Patients with Hemophilia. <i>New England Journal of Medicine</i> , 2009, 360, 1618-1627.	13.9	177
79	Evaluation and Management of Hereditary Hemophilia in the Emergency Department. <i>Journal of Emergency Nursing</i> , 2009, 35, 437-441.	0.5	6
80	Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C→T mutation. <i>Haemophilia</i> , 2009, 15, 91-100.	1.0	19
81	Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. <i>Haemophilia</i> , 2009, 15, 83-90.	1.0	90
82	Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre. <i>Haemophilia</i> , 2009, 15, 285-289.	1.0	34
83	Registry of inherited coagulopathies in Brazil: first report. <i>Haemophilia</i> , 2009, 15, 142-149.	1.0	30
84	Experience with a third generation recombinant factor VIII concentrate (Advate <sup>®</sup> ) for immune tolerance induction in patients with haemophilia A. <i>Haemophilia</i> , 2009, 15, 718-726.	1.0	20
85	Depression, anxiety and suicidal behaviour in children and adolescents with Haemophilia. <i>Haemophilia</i> , 2009, 15, 528-532.	1.0	26
86	Thrombin generation and bleeding in haemophilia A. <i>Haemophilia</i> , 2009, 15, 1118-1125.	1.0	53
87	Haemophilia in Spain. <i>Haemophilia</i> , 2009, 15, 665-675.	1.0	49
88	Controversies regarding the prophylactic management of adults with severe haemophilia A. <i>Haemophilia</i> , 2009, 15, 5-22.	1.0	19
89	Evaluation and performance characteristics of the coagulation system: ACL TOP analyzer and HemosIL reagents. <i>International Journal of Laboratory Hematology</i> , 2009, 31, 26-35.	0.7	38
90	Kinetics of factor VIII:C inhibitors and treatment response in severe hemophilia A patients. <i>International Journal of Laboratory Hematology</i> , 2009, 31, 673-682.	0.7	5
91	Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-α and cytotoxic T lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 2006-2015.	1.9	152
92	Genotype Analysis Identifies the Cause of the "Royal Disease". <i>Science</i> , 2009, 326, 817-817.	6.0	99
93	Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification. <i>Translational Research</i> , 2009, 153, 114-117.	2.2	10

#	ARTICLE	IF	CITATIONS
94	3. Reading of Examination of Platelets and Coagulation/fibrinolytic System. The Journal of the Japanese Society of Internal Medicine, 2009, 98, 1569-1574.	0.0	0
95	How we treat a hemophilia A patient with a factor VIII inhibitor. Blood, 2009, 113, 11-17.	0.6	151
96	Quantitation of anti-factor VIII antibodies in human plasma. Blood, 2009, 113, 2587-2594.	0.6	51
97	Is VIII worse than IX?. Blood, 2009, 114, 750-751.	0.6	32
98	Total knee replacement in patients with end-stage haemophilic arthropathy. Journal of Bone and Joint Surgery: British Volume, 2010, 92-B, 1085-1089.	3.4	90
100	Mutation analysis of factor VIII in Korean patients with severe hemophilia A. International Journal of Hematology, 2010, 91, 784-791.	0.7	8
101	Severe hemophilia A in a Japanese female caused by an F8-intron 22 inversion associated with skewed X chromosome inactivation. International Journal of Hematology, 2010, 92, 405-408.	0.7	8
102	Factor VIII gene mutations profile in 148 Chinese hemophilia A subjects. European Journal of Haematology, 2010, 85, 264-272.	1.1	20
103	Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. Journal of Thrombosis and Haemostasis, 2010, 8, 276-285.	1.9	60
104	Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia, 2010, 16, 263-271.	1.0	46
105	Spectrum of F8 gene mutations in haemophilia A patients from a region of Italy: identification of 23 new mutations. Haemophilia, 2010, 16, 791-800.	1.0	17
106	Meeting unmet needs in inhibitor patients. Haemophilia, 2010, 16, 46-51.	1.0	16
107	Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications. Haemophilia, 2010, 16, 13-17.	1.0	86
108	Tests of global haemostasis and their applications in bleeding disorders. Haemophilia, 2010, 16, 85-92.	1.0	75
109	Pathophysiology of Bleeding and Clotting in the Cardiac Surgery Patient. Circulation, 2010, 122, 2068-2077.	1.6	63
110	Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. , 2010, , CD004449.		32
112	Hemophilia Carrier Status and Counseling the Symptomatic and Asymptomatic Adolescent. Journal of Pediatric and Adolescent Gynecology, 2010, 23, S43-S47.	0.3	13
113	Comprehensive Treatment of Periodontitis in Patients With von Willebrand Disease. Journal of Periodontology, 2010, 81, 1432-1440.	1.7	11

#	ARTICLE	IF	CITATIONS
114	Novel drugs to treat hemophilia. Expert Opinion on Emerging Drugs, 2010, 15, 597-613.	1.0	7
116	Consensus statement by hospital based dentists providing dental treatment for patients with inherited bleeding disorders*. Australian Dental Journal, 2011, 56, 221-226.	0.6	30
117	Hemofilia: ejercicio y deporte. Apunts Medicine De L'Esport, 2011, 46, 29-39.	0.5	8
118	Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B. Thrombosis and Haemostasis, 2011, 105, 616-625.	1.8	1
119	Haemophilia and Joint Disease: Pathophysiology, Evaluation, and Management. Journal of Comorbidity, 2011, 1, 51-59.	3.9	111
120	Haemophilia B: impact on patients and economic burden of disease. Thrombosis and Haemostasis, 2011, 106, 398-404.	1.8	54
121	Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein. Blood, 2011, 117, 3190-3198.	0.6	19
122	Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. British Journal of Clinical Pharmacology, 2011, 72, 553-562.	1.1	84
123	von Willebrand factor: what is its role in the immune response in haemophilia?. Haemophilia, 2011, 17, e235-8.	1.0	7
124	Measurement of factor VIII activity using one-stage clotting assay: a calibration curve has not to be systematically included in each run. Haemophilia, 2011, 17, 139-142.	1.0	13
125	Prophylaxis therapy in haemophilia A: current situation in Spain. Haemophilia, 2011, 17, 75-80.	1.0	14
126	Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia, 2011, 17, 41-44.	1.0	174
127	Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia, 2011, 17, 275-281.	1.0	39
128	Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia, 2011, 17, 282-287.	1.0	62
129	Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A. Haemophilia, 2011, 17, 490-493.	1.0	6
130	Clinical severity of haemophilia A: does the classification of the 1950s still stand?. Haemophilia, 2011, 17, 849-853.	1.0	212
131	Treatment of haemophilia: building on strength in the third millennium. Haemophilia, 2011, 17, 1-24.	1.0	16
132	Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochemical Pharmacology, 2011, 82, 91-98.	2.0	23

#	ARTICLE	IF	CITATIONS
133	Imaging findings in spinal subarachnoid hemorrhage in patient with hemophilia A: an unusual cause for back pain. <i>Emergency Radiology</i> , 2011, 18, 173-175.	1.0	2
134	Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. <i>Expert Review of Hematology</i> , 2011, 4, 539-549.	1.0	27
135	Recombinant FIXFc: a novel therapy for the royal disease?. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1361-1368.	1.4	11
136	New treatments in hemophilia: insights for the clinician. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 165-175.	1.1	12
137	Inherited disorders of blood coagulation. <i>Annals of Medicine</i> , 2012, 44, 405-418.	1.5	21
138	An algorithmic approach to peripheral artery disease in hemophilia. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 23-29.	0.5	4
139	The Patient Experience of Hemophilia and Human Immunodeficiency Virus: A Systematic Review of Qualitative Evidence. <i>JBIC Database of Systematic Reviews and Implementation Reports</i> , 2012, 10, 4659-4668.	1.7	0
141	Modern haemophilia care. <i>Lancet, The</i> , 2012, 379, 1447-1456.	6.3	266
142	Spectrum of <i>F8</i> gene mutations in haemophilia A patients from Slovenia. <i>Haemophilia</i> , 2012, 18, e420-3.	1.0	3
143	Management of joint bleeding in hemophilia. <i>Expert Review of Hematology</i> , 2012, 5, 459-468.	1.0	48
144	Hemophilia management in transfusion medicine. <i>Transfusion and Apheresis Science</i> , 2012, 46, 299-307.	0.5	5
145	Octocog Alfa, Antihaemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate®). <i>Drugs</i> , 2012, 72, 987-1007.	4.9	12
147	Pharmaceutical therapies to recode nonsense mutations in inherited diseases. , 2012, 136, 227-266.		122
148	Haemophilia B: current pharmacotherapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2053-2063.	0.9	22
149	11 Hämophilie A und B. , 2012, , .		0
150	Eradication of factor viii inhibitors in patients with mild and moderate hemophilia A. <i>American Journal of Hematology</i> , 2012, 87, 933-936.	2.0	34
151	Inhibitor development in two patients with mild haemophilia A – spontaneous disappearance and no recurrence of the inhibitor after re-challenge. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 198-201.	1.0	1
152	Molecular diagnosis of haemophilia A at Centro Hospitalar de Coimbra in Portugal: study of 103 families – 15 new mutations. <i>Haemophilia</i> , 2012, 18, 129-138.	1.0	9

#	ARTICLE	IF	CITATIONS
153	Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the South of Brazil. <i>Haemophilia</i> , 2012, 18, e236-40.	1.0	15
154	Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. <i>Haemophilia</i> , 2012, 18, 139-145.	1.0	34
155	The natural history of mild haemophilia: a 30-year single centre experience. <i>Haemophilia</i> , 2012, 18, 166-174.	1.0	36
156	The influence of prophylactic factor VIII in severe haemophilia A. <i>Haemophilia</i> , 2012, 18, 193-199.	1.0	13
157	Computational and molecular approaches for predicting unreported causal missense mutations in Belgian patients with haemophilia A. <i>Haemophilia</i> , 2012, 18, e331-9.	1.0	11
158	Determination of foetal sex in pregnancies at risk of haemophilia: a qualitative study exploring the clinical practices and attitudes of health professionals in the United Kingdom. <i>Haemophilia</i> , 2012, 18, 575-583.	1.0	25
159	A Modified I-PCR to detect the factor VIII Inv22 for genetic diagnosis and prenatal diagnosis in haemophilia A. <i>Haemophilia</i> , 2012, 18, 452-456.	1.0	8
160	A qualitative study identifying the knowledge, attitudes and behaviours of young men with mild haemophilia. <i>Haemophilia</i> , 2012, 18, e120-5.	1.0	28
161	Prenatal diagnosis for haemophilia: a nationwide survey among female carriers in the Netherlands. <i>Haemophilia</i> , 2012, 18, 584-592.	1.0	25
162	Quality of life in adult patients with haemophilia – a single centre experience from Sweden. <i>Haemophilia</i> , 2012, 18, 527-531.	1.0	43
163	Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 82-93.	2.0	73
164	The impact of a specific aqua-training for adult haemophilic patients – results of the WATERCISE study (WAT-QoL). <i>Haemophilia</i> , 2012, 18, 714-721.	1.0	23
165	Clinical trial design in haemophilia. <i>Haemophilia</i> , 2012, 18, 18-23.	1.0	22
166	Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients. <i>Haemophilia</i> , 2012, 18, 794-797.	1.0	23
167	Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A. <i>Haemophilia</i> , 2012, 18, 1003-1007.	1.0	9
168	Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 615-621.	1.9	362
169	Guidelines for the management of hemophilia. <i>Haemophilia</i> , 2013, 19, e1-47.	1.0	1,538
170	Nuclear factor (NF)κB and its associated pathways are major molecular regulators of blood-induced joint damage in a murine model of hemophilia. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 293-306.	1.9	61

#	ARTICLE	IF	CITATIONS
171	A Strategy for the Molecular Diagnosis in Hemophilia A in Chinese Population. <i>Cell Biochemistry and Biophysics</i> , 2013, 65, 463-472.	0.9	7
172	Is haemophilia B less severe than haemophilia A?. <i>Haemophilia</i> , 2013, 19, 499-502.	1.0	61
173	An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1329-1340.	1.9	138
174	Factor VIII Products and Inhibitor Development in Severe Hemophilia A. <i>New England Journal of Medicine</i> , 2013, 368, 231-239.	13.9	383
175	High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance. <i>Journal of Hematology and Oncology</i> , 2013, 6, 63.	6.9	15
176	Cross-cultural adaptation and linguistic validation of age-group-specific haemophilia patient-reported outcome (PRO) instruments for patients and parents. <i>Haemophilia</i> , 2013, 19, e73-83.	1.0	32
177	Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1655-1662.	1.9	59
178	The Reversal of Inhibitors in Congenital Hemophilia. <i>Pharmacotherapy</i> , 2013, 33, 157-164.	1.2	8
179	Health-related quality of life in haemophilia patients with inhibitors and their caregivers. <i>Haemophilia</i> , 2013, 19, 287-293.	1.0	41
180	Percutaneous coronary intervention in patients with haemophilia presenting with acute coronary syndrome: an interventional dilemma: case series, review of the literature, and tips for management. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 271-278.	1.0	14
181	The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online Resource. <i>Human Mutation</i> , 2013, 34, E2382-E2392.	1.1	52
182	Inherited Abnormalities of Coagulation. <i>Pediatric Clinics of North America</i> , 2013, 60, 1419-1441.	0.9	34
183	Development of factor VIII inhibitors in two patients with moderate haemophilia A. <i>Haemophilia</i> , 2013, 19, e55-7.	1.0	3
184	Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden. <i>Haemophilia</i> , 2013, 19, 362-369.	1.0	60
185	Genotypic and phenotypic features of Japanese patients with mild to moderate hemophilia A. <i>International Journal of Hematology</i> , 2013, 97, 758-764.	0.7	3
186	Detection of new mutations and molecular pathology of mild and moderate haemophilia A patients from southern Brazil. <i>Haemophilia</i> , 2013, 19, 773-781.	1.0	9
187	Renal diseases in haemophilic patients: pathogenesis and clinical management. <i>European Journal of Haematology</i> , 2013, 91, 287-294.	1.1	20
188	Radiosynovectomy. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 465-470.	0.5	30

#	ARTICLE	IF	CITATIONS
189	Genetic changes in severe haemophilia A. Blood Coagulation and Fibrinolysis, 2013, 24, 164-169.	0.5	5
190	Factors that influence the bleeding phenotype in severe hemophilic patients. Blood Coagulation and Fibrinolysis, 2013, 24, 683-690.	0.5	19
191	Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Therapeutic Advances in Hematology, 2013, 4, 59-72.	1.1	172
192	Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the <sc>UDC</sc> database. Haemophilia, 2013, 19, 426-431.	1.0	14
193	Prenatal diagnosis of haemophilia B: the Italian experience. Haemophilia, 2013, 19, 898-903.	1.0	6
194	The <sc>CDC</sc> Hemophilia B mutation project mutation list: a new online resource. Molecular Genetics & Genomic Medicine, 2013, 1, 238-245.	0.6	49
195	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, 2013, 121, 4046-4055.	0.6	287
196	Management of severe perioperative bleeding. European Journal of Anaesthesiology, 2013, 30, 270-382.	0.7	740
198	Congenital Coagulopathies. , 2014, , 1562-1574.		0
199	Platelet degranulation and glycoprotein IIb/IIIa opening are not related to bleeding phenotype in severe haemophilia A patients. Thrombosis and Haemostasis, 2014, 111, 1022-1030.	1.8	4
200	Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays. Thrombosis and Haemostasis, 2014, 112, 851-861.	1.8	58
201	Treatment options for haemophilic arthropathy of the elbow after failed conservative therapy. Hamostaseologie, 2014, 34, S17-S22.	0.9	4
202	The role of Rixubisâ„¢ in the treatment of hemophilia B. Immunotherapy, 2014, 6, 381-394.	1.0	5
203	Plasma Components as Targets of Damage. , 2014, , 3150-3165.		0
204	Impact of health instructions on improving knowledge and practices of haemophilia A adolescents: a single centre experience. Haemophilia, 2014, 20, e260-6.	1.0	7
205	Prevalent inhibitors in haemophilia <sc>B</sc> subjects enrolled in the <sc>U</sc>niversal <sc>D</sc>ata <sc>C</sc>ollection database. Haemophilia, 2014, 20, 25-31.	1.0	56
206	Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTSâ€13 activity. Haemophilia, 2014, 20, 92-98.	1.0	9
207	Lack of seasonal variation in bleeding and patientâ€™s assessed pain patterns in patients with haemophilia B receiving onâ€demand therapy. Haemophilia, 2014, 20, 349-353.	1.0	10

#	ARTICLE	IF	CITATIONS
208	An overview of current trends and gaps in patient-reported outcome measures used in haemophilia. <i>European Journal of Haematology</i> , 2014, 93, 1-8.	1.1	14
209	Haemophilia care “beyond the treatment guidelines. <i>Haemophilia</i> , 2014, 20, 4-10.	1.0	18
210	Coping in adult patients with severe haemophilia. <i>Haemophilia</i> , 2014, 20, 513-518.	1.0	16
211	Total ankle replacement in patients with haemophilia and virus infections “a safe alternative to ankle arthrodesis?. <i>Haemophilia</i> , 2014, 20, 702-708.	1.0	30
212	Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia and inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 897-901.	1.9	11
213	Factor VIII therapy for hemophilia A: current and future issues. <i>Expert Review of Hematology</i> , 2014, 7, 373-385.	1.0	27
214	Difficult encounters with a hemophilic patient: The inner perspective of physicians. <i>Journal of Health Psychology</i> , 2014, 19, 1499-1507.	1.3	7
216	Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1861-1873.	1.9	7
217	Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 210-215.	1.0	4
219	Orthopaedic and surgical features in the management of patients with haemophilia. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2014, 24, 685-692.	0.6	8
220	The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 356-363.	0.3	15
221	First Molecular Analysis of <i>F8</i> Gene in Algeria. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 741-748.	0.7	2
222	Considerations in individualizing prophylaxis in patients with haemophilia A. <i>Haemophilia</i> , 2014, 20, 607-615.	1.0	55
223	Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A. <i>Haemophilia</i> , 2014, 20, 624-629.	1.0	10
224	Characterization of four novel molecular changes in the promoter region of the factor VIII gene. <i>Haemophilia</i> , 2014, 20, e149-56.	1.0	6
225	Bleeding diathesis and hemophilias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 120, 1045-1059.	1.0	4
226	Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. <i>Haemophilia</i> , 2014, 20, 747-755.	1.0	35
227	Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. <i>Haemophilia</i> , 2014, 20, e243-50.	1.0	19

#	ARTICLE	IF	CITATIONS
229	Physical and mental quality of life in adult patients with haemophilia in Belgium: the impact of financial issues. <i>Haemophilia</i> , 2014, 20, 479-485.	1.0	19
230	Definitions in hemophilia: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1935-1939.	1.9	530
231	Mutation analysis of a cohort of US patients with hemophilia B. <i>American Journal of Hematology</i> , 2014, 89, 375-379.	2.0	22
232	Diagnosis and management challenges in patients with mild haemophilia A and discrepant <scp>FVIII</scp> measurements. <i>Haemophilia</i> , 2014, 20, 550-558.	1.0	43
233	Effect of resistance and aerobic exercises on bone mineral density, muscle strength and functional ability in children with hemophilia. <i>Egyptian Journal of Medical Human Genetics</i> , 2014, 15, 139-147.	0.5	20
234	Verification of the guidelines for lupus anticoagulant detection: Usefulness of index for circulating anticoagulant in APTT mixing test. <i>Thrombosis Research</i> , 2014, 134, 503-509.	0.8	12
235	Evaluation and Management of Congenital Bleeding Disorders. <i>Emergency Medicine Clinics of North America</i> , 2014, 32, 673-690.	0.5	7
236	Effect of F8 B domain gene variants on synthesis, secretion, activity and stability of factor VIII protein. <i>Thrombosis and Haemostasis</i> , 2014, 111, 58-66.	1.8	9
239	Using genetic diagnostics in hemophilia and von Willebrand disease. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 152-159.	0.9	15
240	Osmotically driven drug delivery through remote-controlled magnetic nanocomposite membranes. <i>Biomicrofluidics</i> , 2015, 9, 054113.	1.2	15
241	<i>In silico</i> analyses of missense mutations in coagulation factor <scp>VIII</scp>: identification of severity determinants of haemophilia A. <i>Haemophilia</i> , 2015, 21, 662-669.	1.0	17
242	International cross-cultural validation study of the Canadian Haemophilia Outcomes: Kids™ Life Assessment Tool. <i>Haemophilia</i> , 2015, 21, 351-357.	1.0	26
243	Inhibitor development in non-severe haemophilia across Europe. <i>Thrombosis and Haemostasis</i> , 2015, 114, 670-675.	1.8	14
244	Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. <i>Thrombosis and Haemostasis</i> , 2015, 114, 804-811.	1.8	19
245	Rationale for individualizing haemophilia care. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 849-857.	0.5	19
246	A standardized treatment regimen for patients with severe haemophilia A undergoing orthopaedic or trauma surgery. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 396-402.	0.5	2
247	Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. <i>The Cochrane Library</i> , 2020, 2020, CD004449.	1.5	21
248	Self-reported activity and functioning in daily life; the perspective of persons with haemophilia living in Sweden. <i>European Journal of Haematology</i> , 2015, 95, 336-341.	1.1	9

#	ARTICLE	IF	CITATIONS
249	Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. <i>Haemophilia</i> , 2015, 21, 550-557.	1.0	60
250	Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study). <i>Haemophilia</i> , 2015, 21, 736-741.	1.0	26
251	Novel mutations associated with a discrepancy between one-stage and chromogenic FVIII activity assays. <i>Haemophilia</i> , 2015, 21, e330-2.	1.0	10
252	Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?. <i>Haemophilia</i> , 2015, 21, 709-714.	1.0	19
253	A Cohort Pilot Study on HIV-Associated Neuropsychological Impairments in Hemophilia Patients. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 313.	1.0	18
254	Christmas disease: diagnosis and management of a haemorrhagic diathesis following dentofacial trauma. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014203790-bcr2014203790.	0.2	5
255	Anesthesia in Orthopedic Surgery of the Adult Hemophilia Patient. , 2015, , 105-110.		0
256	How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors. <i>Blood</i> , 2015, 126, 153-159.	0.6	14
257	Prevention of bleeding in hemophilia patients with high-titer inhibitors. <i>Expert Review of Hematology</i> , 2015, 8, 375-382.	1.0	3
258	Heavy hematuria requiring cystectomy in a patient with hemophilia A: a case report and literature review. <i>BMC Urology</i> , 2015, 15, 84.	0.6	6
260	A Guide to Performing Cardiac Surgery in Patients with Hereditary Bleeding Disorders. <i>Journal of Cardiac Surgery</i> , 2015, 30, 61-69.	0.3	23
261	Identification of six novel F9 mutations among haemophilia B patients from Macedonia and Bulgaria. <i>Haemophilia</i> , 2015, 21, e144-6.	1.0	0
262	Oral surgery-associated postoperative bleeding in haemophilia patients – a tertiary centre's two decade experience. <i>Haemophilia</i> , 2015, 21, 234-240.	1.0	15
263	Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. <i>The Cochrane Library</i> , 2015, , CD009961.	1.5	30
264	Identification of ten novel mutations in factor VIII gene: A study of a cohort of 52 haemophilia A patients. <i>Thrombosis Research</i> , 2015, 135, 1031-1034.	0.8	1
265	Actualité sur le risque de survenue d'un inhibiteur à l'initiation du traitement par concentré de facteur VIII dans l'hémophilie A sévère. <i>Revue D'Oncologie Hématologie Pédiatrique</i> , 2015, 3, 78-87.	0.1	0
266	Assessment of Musculoskeletal Function and its Correlation with Radiological Joint Score in Children with Hemophilia A. <i>Indian Journal of Pediatrics</i> , 2015, 82, 1101-1106.	0.3	5
267	Factors influencing illness representations and perceived adherence in haemophilic patients: a pilot study. <i>Haemophilia</i> , 2015, 21, 598-604.	1.0	27

#	ARTICLE	IF	CITATIONS
268	Usefulness of an <i>in vitro</i> cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the <i>F8</i> gene in women with isolated factor VIII:C deficiency. <i>Haemophilia</i> , 2015, 21, e202-9.	1.0	7
269	Anti- $\text{A}2$ and anti- $\text{A}1$ domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 540-547.	1.9	13
270	Inhibitors in haemophilia: what have we learned from registries? A systematic review. <i>Journal of Internal Medicine</i> , 2015, 277, 1-15.	2.7	27
271	Detection of mild inherited disorders of blood coagulation: current options and personal recommendations. <i>Expert Review of Hematology</i> , 2015, 8, 527-542.	1.0	30
272	Incidence of symptomatic venous thromboembolism in patients with hemophilia undergoing joint replacement surgery: A retrospective study. <i>Thrombosis Research</i> , 2015, 135, 109-113.	0.8	36
273	Co-Infection of the Hepatitis C Virus With Other Blood-Borne and Hepatotropic Viruses Among Hemophilia Patients in Poland. <i>Hepatitis Monthly</i> , 2016, 16, e35658.	0.1	11
274	Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries. <i>Thrombosis and Haemostasis</i> , 2016, 116, 32-41.	1.8	4
275	The Role of Frontal-Subcortical Circuitry in Neuropsychological Deficit of Attention: Hypothesis and Results in Two Coagulation Disorders. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 89.	1.0	4
276	Mini-gene assays confirm the splicing effect of deep intronic variants in the factor VIII gene. <i>Thrombosis and Haemostasis</i> , 2016, 115, 222-224.	1.8	7
277	The utility of thromboelastography in inherited and acquired bleeding disorders. <i>British Journal of Haematology</i> , 2016, 174, 503-514.	1.2	92
278	Assessment of the frequency of regulatory T cells (CD4+CD25+CD127 <sup>hi</sup> ) in children with hemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 42-46.	0.5	2
279	Prophylaxis vs. on-demand treatment with Nuwiq <sup>®</sup> (Human $\text{rFVIIc}$ ) in adults with severe haemophilia A. <i>Haemophilia</i> , 2016, 22, 374-380.	1.0	32
280	Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice. <i>Haemophilia</i> , 2016, 22, 453-461.	1.0	2
281	Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. <i>Gene Therapy</i> , 2016, 23, 699-707.	2.3	125
282	The safety of pharmacologic options for the treatment of persons with hemophilia. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1391-1400.	1.0	12
283	Declining trends in invasive orthopedic interventions for people with hemophilia enrolled in the Universal Data Collection program (2000-2010). <i>Haemophilia</i> , 2016, 22, 604-614.	1.0	11
284	COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 337-347.	0.2	10
285	Alteraciones del sistema hemostático. Estrategias diagnósticas de la patología hemorrágica. <i>Coagulopatías congénitas</i> . <i>Medicine</i> , 2016, 12, 1255-1266.	0.0	0

#	ARTICLE	IF	CITATIONS
286	A genetic analysis of 23 Chinese patients with hemophilia B. <i>Scientific Reports</i> , 2016, 6, 25024.	1.6	3
287	Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO <sup>®</sup> ) in subjects with haemophilia A (SWIFT-HA study). <i>Thrombosis Research</i> , 2016, 137, 119-125.	0.8	7
288	Factor VIII <sup>ΔE</sup> Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. <i>New England Journal of Medicine</i> , 2016, 374, 2044-2053.	13.9	373
289	<sc>CRISPR</sc> /Cas9 <sup>ΔE</sup> mediated somatic correction of a novel coagulator factor <sc>IX</sc> gene mutation ameliorates hemophilia in mouse. <i>EMBO Molecular Medicine</i> , 2016, 8, 477-488.	3.3	144
290	Study of six patients with complete F9 deletion characterized by cytogenetic microarray: role of the SOX3 gene in intellectual disability. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1988-1993.	1.9	10
291	Novel, human cell line <sup>ΔE</sup> derived recombinant factor <sc>VIII</sc> (Human <sup>ΔE</sup> rh<sc>FVIII</sc>), Tj ETQq1 1 0.784314 rgBT /Overd... Haemophilia, 2016, 22, 232-239.	1.0	44
292	Dosing regimens, <sc>FVIII</sc> levels and estimated haemostatic protection with special focus on <sc>rFVIII</sc>. <i>Haemophilia</i> , 2016, 22, 389-396.	1.0	33
293	First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. <i>Haemophilia</i> , 2016, 22, 87-95.	1.0	47
294	Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1668-1672.	1.9	6
295	Evaluation of the utility of the <sc>ISTH</sc> <sup>ΔE</sup> <sc>BAT</sc> in haemophilia carriers: a multinational study. <i>Haemophilia</i> , 2016, 22, 912-918.	1.0	60
296	Non <sup>ΔE</sup> genetic risk factors in haemophilia A inhibitor management <sup>ΔE</sup> the danger theory and the use of animal models. <i>Haemophilia</i> , 2016, 22, 657-666.	1.0	32
297	Epidemiological aspects of inhibitor development in hemophilia and strategies of management. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 153-168.	0.5	0
299	Serum cartilage oligomeric matrix protein reflects radiological damage and functional status in hemophilic arthropathy patients. <i>Egyptian Rheumatologist</i> , 2016, 38, 241-245.	0.5	5
300	Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. <i>British Journal of Haematology</i> , 2016, 174, 454-460.	1.2	46
301	Distinct X chromosomal rearrangements in four haemophilia B patients with entire <i>F9</i> deletion. <i>Haemophilia</i> , 2016, 22, 433-439.	1.0	4
302	Characterization of five associations of <i>F8</i> missense mutations containing <sc>FVIII</sc> B domain mutations. <i>Haemophilia</i> , 2016, 22, 583-589.	1.0	11
303	A germline variant affects putative mi<sc>RNA</sc> binding sites at the <i>F8</i> 3 <sup>ΔE</sup> <sc>UTR</sc> and acts as a potential haemophilia A phenotype modifier in Southern Brazilian patients. <i>Haemophilia</i> , 2016, 22, e327-9.	1.0	13
304	Five in one therapy for graded treatment of haemophilic arthritis. <i>Haemophilia</i> , 2016, 22, 208-213.	1.0	4

#	ARTICLE	IF	CITATIONS
305	The past and future of haemophilia: diagnosis, treatments, and its complications. <i>Lancet</i> , The, 2016, 388, 187-197.	6.3	331
306	Design of pH-Responsive Biomaterials to Enable the Oral Route of Hematological Factor IX. <i>Annals of Biomedical Engineering</i> , 2016, 44, 1970-1982.	1.3	15
307	Successful thrombolytic therapy for ST-elevation acute myocardial infarction in a patient with immune thrombocytopenic purpura. <i>American Journal of Emergency Medicine</i> , 2016, 34, 345.e1-345.e3.	0.7	2
308	Gene therapy for hemophilia: past, present and future. <i>Seminars in Hematology</i> , 2016, 53, 46-54.	1.8	33
309	Advances in the clinical management of inhibitors in hemophilia A and B. <i>Seminars in Hematology</i> , 2016, 53, 20-27.	1.8	23
310	Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors. <i>Immunology Letters</i> , 2016, 169, 93-97.	1.1	1
311	Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa). <i>Expert Opinion on Drug Safety</i> , 2017, 16, 405-410.	1.0	4
312	Calidad de vida en una poblaci3n con hemofilia: estudio de corte transversal en un centro de tratamiento de hemofilia. <i>Revista Colombiana De ReumatologAa</i> , 2017, 24, 18-24.	0.0	6
313	Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A. <i>British Journal of Haematology</i> , 2017, 176, 796-804.	1.2	21
314	Recent advances in hemophilia B therapy. <i>Drug Delivery and Translational Research</i> , 2017, 7, 359-371.	3.0	8
315	Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. <i>British Journal of Haematology</i> , 2017, 178, 20-31.	1.2	10
316	Comparative burden of arthropathy in mild haemophilia: a register-based study in Sweden. <i>Haemophilia</i> , 2017, 23, e79-e86.	1.0	19
317	The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register. <i>Haemophilia</i> , 2017, 23, e180-e187.	1.0	11
318	The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia. <i>Medicine (United Tj ETQq1 1 0,784314 rgBT /Over</i>	0.4	16
319	CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice. <i>Human Genetics</i> , 2017, 136, 875-883.	1.8	56
320	Molecular cytogenetic characterization of five F8 complex rearrangements: utility for haemophilia A genetic counselling. <i>Haemophilia</i> , 2017, 23, e316-e323.	1.0	7
321	Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B. <i>Haemophilia</i> , 2017, 23, 620-627.	1.0	34
322	Progress in the contemporary management of hemophilia: The new issue of patient aging. <i>European Journal of Internal Medicine</i> , 2017, 43, 16-21.	1.0	26

#	ARTICLE	IF	CITATIONS
323	Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products. <i>Haemophilia</i> , 2017, 23, 705-711.	1.0	14
324	A Case of Hemophilia A Presenting in a Neonate and a Review of the Literature. <i>Global Pediatric Health</i> , 2017, 4, 2333794X1769311.	0.3	1
325	Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII. <i>Scientific Reports</i> , 2017, 7, 45033.	1.6	9
326	Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B. <i>Drugs</i> , 2017, 77, 97-106.	4.9	30
327	Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 246-254.	1.9	24
328	Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. <i>Haemophilia</i> , 2017, 23, e536-e538.	1.0	18
329	Evaluation and Management of Congenital Bleeding Disorders. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 1105-1122.	0.9	3
330	Evidence-Based Management of the Knee in Hemophilia. <i>JBJS Reviews</i> , 2017, 5, e12-e12.	0.8	19
331	Clot waveform analysis using CS <sub>2000</sub> distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A. <i>Haemophilia</i> , 2017, 23, e427-e435.	1.0	30
332	IgG subclasses of FVIII inhibitors in an argentine cohort of severe hemophilia A patients: Analysis by flow cytometry. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 569-576.	0.7	0
333	To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity. <i>Blood Reviews</i> , 2017, 31, 339-347.	2.8	30
334	Quality of life in a population with haemophilia: A cross-sectional study from a single haemophilia treatment center. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2017, 24, 18-24.	0.1	1
335	One-Stage Factor VIII Assays. <i>Methods in Molecular Biology</i> , 2017, 1646, 247-263.	0.4	27
337	Management of Hemophilia in Older Patients. <i>Drugs and Aging</i> , 2017, 34, 881-889.	1.3	6
338	Nonacog Beta Pegol: A Review in Haemophilia B. <i>Drugs</i> , 2017, 77, 2003-2012.	4.9	7
339	Evaluation of a web-based registry of inherited bleeding disorders: a descriptive study of the Brazilian experience with HEMOVIDAweb Coagulopatias. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 27.	1.2	17
340	A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity. <i>International Journal of Hematology</i> , 2017, 105, 174-183.	0.7	36
341	Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1023-1030.	1.8	36

#	ARTICLE	IF	CITATIONS
342	Repeated Diffuse Alveolar Hemorrhage in a Patient with Hemophilia B. <i>Internal Medicine</i> , 2017, 56, 425-428.	0.3	1
343	Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX. <i>Journal of Clinical Medicine</i> , 2017, 6, 46.	1.0	53
344	Hemophilia Care in the Pediatric Age. <i>Journal of Clinical Medicine</i> , 2017, 6, 54.	1.0	39
345	Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A. <i>Frontiers in Immunology</i> , 2017, 8, 1604.	2.2	28
346	Molecular Diagnostics for Coagulopathies. , 2017, , 221-233.		0
347	Cross-reacting Material-positive Hemophilia A Diagnosed in a Patient with a Spontaneous Thigh Hemorrhage. <i>Internal Medicine</i> , 2017, 56, 1719-1723.	0.3	0
348	Recurrent <i>F8</i> and <i>F9</i> gene variants result from a founder effect in two large French haemophilia cohorts. <i>Haemophilia</i> , 2018, 24, e213-e221.	1.0	3
349	Clinical trials and registries in haemophilia: Opponents or collaborators? Comparison of PUP data derived from different data sources. <i>Haemophilia</i> , 2018, 24, 420-428.	1.0	6
350	High proportion of patients with bleeding of unknown cause in persons with a mild to moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB). <i>Haemophilia</i> , 2018, 24, 405-413.	1.0	49
351	Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B. <i>Haemophilia</i> , 2018, 24, 414-419.	1.0	38
352	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 778-790.	1.9	23
353	Novel therapies and current clinical progress in hemophilia A. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 49-61.	1.1	36
354	Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?. <i>Blood Reviews</i> , 2018, 32, 265-271.	2.8	41
355	Reccurent F8 Intronic Deletion Found in Mild Hemophilia A Causes Alu Exonization. <i>American Journal of Human Genetics</i> , 2018, 102, 199-206.	2.6	26
356	The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. <i>Pilot and Feasibility Studies</i> , 2018, 4, 58.	0.5	34
357	The rare coexistence of high titer inhibitor development and gastrointestinal stromal tumor in a patient with severe hemophilia: A case report. <i>Transfusion and Apheresis Science</i> , 2018, 57, 398-400.	0.5	1
358	Health-Related Quality of Life and Psychological Aspects of Adults With Hemophilia in Iran. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1073-1081.	0.7	30
359	Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective. <i>Human Gene Therapy Clinical Development</i> , 2018, 29, 80-89.	3.2	10

#	ARTICLE	IF	CITATIONS
360	Efficacy of pulsed high-intensity laser therapy on pain, functional capacity, and gait in children with haemophilic arthropathy. <i>Disability and Rehabilitation</i> , 2018, 40, 462-468.	0.9	17
361	Spectrum of Molecular Defects in 216 Chinese Families With Hemophilia A: Identification of Noninversion Mutation Hot Spots and 42 Novel Mutations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 70-78.	0.7	12
362	Production of Recombinant Factor VIII in Human Cell Lines. <i>Methods in Molecular Biology</i> , 2018, 1674, 63-74.	0.4	6
363	Major bleeding disorders: diagnosis, classification, management and recent developments in haemophilia. <i>Archives of Disease in Childhood</i> , 2018, 103, 509-513.	1.0	5
364	Gene therapy with adeno-associated virus vector 5â€“human factor IX in adults with hemophilia B. <i>Blood</i> , 2018, 131, 1022-1031.	0.6	236
365	Breakâ€“through bleeding in relation to pharmacokinetics of Factor <scp>VIII</scp> in paediatric patients with severe haemophilia A. <i>Haemophilia</i> , 2018, 24, 120-125.	1.0	3
366	Long-term results of total elbow arthroplasty in patients with hemophilia. <i>Journal of Shoulder and Elbow Surgery</i> , 2018, 27, 126-132.	1.2	23
367	Cytokines in the pathogenesis of hemophilic arthropathy. <i>Cytokine and Growth Factor Reviews</i> , 2018, 39, 71-91.	3.2	30
368	Initial Manifestation of Acquired Hemophilia A After a Routine Tooth Extraction. A Case Report and Literature Review. <i>Journal of Oral and Maxillofacial Surgery</i> , 2018, 76, 490-494.	0.5	4
369	Tolerance induction in hemophilia. <i>Current Opinion in Hematology</i> , 2018, 25, 365-372.	1.2	14
370	Carriers of Hemophilia A and Hemophilia B. , 0, , 65-82.		0
371	Combination of novoseven and feiba in hemophilic patients with inhibitors. <i>Open Medicine (Poland)</i> , 2018, 13, 618-621.	0.6	5
372	A new measure to assess pain in people with haemophilia: The Multidimensional Haemophilia Pain Questionnaire (MHPQ). <i>PLoS ONE</i> , 2018, 13, e0207939.	1.1	14
373	Comparison of Total Joint Replacement Rate Between Patients With Hemophilia A and Patients With Hemophilia B: A Population-Based and Retrospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 163S-170S.	0.7	4
374	Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX. <i>Blood Research</i> , 2018, 53, 41.	0.5	3
375	The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2530-2533.	1.9	53
376	The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 319-334.	1.1	32
377	A Rare Case of Giant Solid Hemangioblastoma Accompanied with Hemophilia Type A. <i>NMC Case Report Journal</i> , 2018, 5, 95-97.	0.2	1

#	ARTICLE	IF	CITATIONS
378	A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples). <i>Thrombosis Research</i> , 2018, 171, 7-13.	0.8	2
379	Orthotopic liver transplantation for haemophilia A may not always lead to a phenotypic cure of haemophilia A: A case report. <i>Haemophilia</i> , 2018, 24, e420-e422.	1.0	4
380	Role of chromogenic assays in haemophilia A and B diagnosis. <i>Haemophilia</i> , 2018, 24, 578-583.	1.0	13
381	Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab. <i>Drugs</i> , 2018, 78, 881-890.	4.9	38
382	Risk factors associated with invasive orthopaedic interventions in males with haemophilia enrolled in the Universal Data Collection program from 2000 to 2010. <i>Haemophilia</i> , 2018, 24, 964-970.	1.0	5
383	Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 632-642.	0.5	35
384	Hemophilia A. , 2018, , 103-137.		2
385	Hemophilia B. , 2018, , 139-160.		5
386	Range of motion after total knee arthroplasty in hemophilic arthropathy. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 162.	0.8	13
387	Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients. <i>Haemophilia</i> , 2018, 24, 807-814.	1.0	10
388	Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 643-653.	0.5	25
389	Clinical relevance of 3D gait analysis in patients with haemophilia. <i>Haemophilia</i> , 2018, 24, 703-710.	1.0	13
390	Issues complicating precision dosing for factor VIII prophylaxis. <i>Transfusion and Apheresis Science</i> , 2018, 57, 472-479.	0.5	7
391	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. <i>BMJ Open</i> , 2018, 8, e021900.	0.8	15
392	Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks. <i>Expert Review of Hematology</i> , 2018, 11, 567-576.	1.0	19
393	The socioeconomic burden of patients affected by hemophilia with inhibitors. <i>European Journal of Haematology</i> , 2018, 101, 435-456.	1.1	37
394	The Japanese Immune Tolerance Induction (ITI) study in haemophilia patients with inhibitor: Outcomes and successful predictors of ITI treatment. <i>Haemophilia</i> , 2018, 24, e328-e337.	1.0	14
395	Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan. <i>International Journal of Hematology</i> , 2019, 109, 70-78.	0.7	4

#	ARTICLE	IF	CITATIONS
396	Decreased bone mineral density and associated factors in severe haemophilia A patients: A case-control study. <i>Haemophilia</i> , 2019, 25, e315-e321.	1.0	12
397	Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnaires. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 335-341.	0.1	15
398	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. <i>Blood</i> , 2019, 134, 317-320.	0.6	71
399	Splicing dysregulation contributes to the pathogenicity of several F9 exonic point variants. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2019, 7, e840.	0.6	13
400	Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. <i>Haemophilia</i> , 2019, 25, 797-806.	1.0	32
401	Orphan drug development: the increasing role of clinical pharmacology. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 395-409.	0.8	12
402	Genotype-Phenotype Heterogeneity in Haemophilia. , 0, , .		2
403	Physical Activity Monitoring and Acceptance of a Commercial Activity Tracker in Adult Patients with Haemophilia. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3851.	1.2	16
404	Enhanced Factor IX Activity following Administration of AAV5-R338L Factor IX versus AAV5 WT Human Factor IX in NHPs. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 221-231.	1.8	19
405	Cost of Patients With Hemophilia A and High-Titer Inhibitors in Colombia. <i>Value in Health Regional Issues</i> , 2019, 20, 164-171.	0.5	1
406	Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia. <i>Haemophilia</i> , 2019, 25, 1083-1091.	1.0	8
407	Polymorphisms in the cytotoxic T lymphocyte-associated protein-4 immune regulatory gene and their impact on inhibitor development in patients with hemophilia A. <i>Journal of International Medical Research</i> , 2019, 47, 4981-4992.	0.4	6
408	The characteristics and spectrum of <i>F9</i> mutations in Chinese sporadic haemophilia B pedigrees. <i>Haemophilia</i> , 2019, 25, 316-323.	1.0	6
409	Splicing analysis of 26 <i>F8</i> nucleotide variations using a minigene assay. <i>Haemophilia</i> , 2019, 25, 306-315.	1.0	15
410	Health Status and Quality of Life in Patients with Severe Hemophilia A: A Cross-Sectional Survey. <i>Hematology Reports</i> , 2019, 11, 7894.	0.3	16
411	Hepatectomy in patients with inherited blood coagulation disorders can be safely performed with adequate coagulation factor replacement. <i>Haemophilia</i> , 2019, 25, 463-467.	1.0	8
412	Polymorphisms in MAPK9 (rs4147385) and CSF1R (rs17725712) are associated with the development of inhibitors in patients with haemophilia A in North China. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 572-577.	0.7	4
413	Emicizumab for the prevention of bleeds in hemophilia A. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 753-761.	1.4	10

#	ARTICLE	IF	CITATIONS
414	Gene Therapy in Pediatric Liver Disease. , 2019, , 799-829.		2
415	Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A. Haemophilia, 2019, 25, 521-526.	1.0	5
416	Impact of prophylaxis on health-related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 397-404.	1.0	12
417	Severe hemophilia A caused by an unbalanced chromosomal rearrangement identified using nanopore sequencing. Journal of Thrombosis and Haemostasis, 2019, 17, 1097-1103.	1.9	10
418	Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. Journal of Thrombosis and Haemostasis, 2019, 17, 1104-1112.	1.9	42
419	Inflammatory and immune response genes: A genetic analysis of inhibitor development in Iranian hemophilia A patients. Pediatric Hematology and Oncology, 2019, 36, 28-39.	0.3	7
420	Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources. Haemophilia, 2019, 25, 456-462.	1.0	15
421	Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy. Medical Journal of Australia, 2019, 210, 326-332.	0.8	20
422	Incidence of Symptomatic Venous Thromboembolism in Patients with Hemophilia Undergoing Hip and Knee Joint Replacement without Chemoprophylaxis: A Retrospective Study. Orthopaedic Surgery, 2019, 11, 236-240.	0.7	12
423	Health-related quality of life in children with haemophilia in China: a 4-year follow-up prospective cohort study. Health and Quality of Life Outcomes, 2019, 17, 28.	1.0	10
424	Perioperative Management of Hemophilia A Using Recombinant Factor VIII in Patients Undergoing Major or Minor Surgery. , 2019, , .		0
425	Vascularized Free Tissue Transfer in a Patient with Hemophilia B: Case Report and Literature Review. Case Reports in Surgery, 2019, 2019, 1-7.	0.2	1
426	Differences in Major Bleeding Events Between Patients With Severe Hemophilia A and Hemophilia B: A Nationwide, Population-Based Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961988802.	0.7	7
427	Development in well-being and social function among Danish hemophilia patients with HIV: a three-wave panel study spanning 24 years. BMC Public Health, 2019, 19, 1714.	1.2	1
428	Thromboelastometry as a diagnostic tool in mild bleeding disorders. European Journal of Anaesthesiology, 2019, 36, 457-465.	0.7	3
429	New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood, 2019, 133, 399-406.	0.6	57
430	Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor <sc>VIII</sc> concentrate: results of the <sc>HEMFIL</sc> Cohort Study. British Journal of Haematology, 2019, 186, 152-155.	1.2	5
431	Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan. International Journal of Hematology, 2019, 109, 336-345.	0.7	6

#	ARTICLE	IF	CITATIONS
432	The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. <i>Haemophilia</i> , 2019, 25, 33-44.	1.0	63
433	Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEADUS) score. <i>Haemophilia</i> , 2019, 25, 144-153.	1.0	11
434	Utility valuation of health states for haemophilia and related complications in Europe and in the United States. <i>Haemophilia</i> , 2019, 25, 92-100.	1.0	8
435	Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. <i>Clinical Chemistry</i> , 2019, 65, 254-262.	1.5	23
436	Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. <i>International Journal of Hematology</i> , 2020, 111, 42-50.	0.7	40
437	Pain Prevalence, Characteristics, and Impact Among People with Hemophilia: Findings from the First Portuguese Survey and Implications for Pain Management. <i>Pain Medicine</i> , 2020, 21, 458-471.	0.9	17
438	Pulsed Nd:YAG laser: effects on pain, postural stability, and weight-bearing pattern in children with hemophilic ankle arthropathy. <i>Lasers in Medical Science</i> , 2020, 35, 1075-1083.	1.0	11
439	Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate-severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 285-294.	1.9	6
440	Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B. <i>European Journal of Haematology</i> , 2020, 104, 3-14.	1.1	22
441	Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges. <i>Thrombosis Research</i> , 2020, 196, 609-617.	0.8	18
442	Detection of intrinsic pathway factor deficiency associated with bleeding risk by kaolin-based aPTT. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e107-e109.	0.7	0
443	Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches. <i>Blood Reviews</i> , 2020, 40, 100641.	2.8	14
444	Bleeding assessment in haemophilia carriers – High rates of bleeding after surgical abortion and intrauterine device placement: A multicentre study in China. <i>Haemophilia</i> , 2020, 26, 122-128.	1.0	8
445	Machine learning method using position-specific mutation based classification outperforms one hot coding for disease severity prediction in haemophilia – A™. <i>Genomics</i> , 2020, 112, 5122-5128.	1.3	21
446	The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 810-818.	0.7	3
447	Characterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay. <i>Blood Advances</i> , 2020, 4, 3659-3667.	2.5	7
448	FVIII Immunogenicity – Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A. <i>Frontiers in Immunology</i> , 2020, 11, 1498.	2.2	0
449	The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole <i>F8</i> gene sequencing and functional assays. <i>Haemophilia</i> , 2020, 26, 1056-1063.	1.0	11

#	ARTICLE	IF	CITATIONS
450	The factor VIII treatment history of non-severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3203-3210.	1.9	15
451	Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?. <i>Italian Journal of Pediatrics</i> , 2020, 46, 129.	1.0	8
452	Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy. <i>Blood</i> , 2020, 136, 2524-2534.	0.6	48
453	Cardiac surgery in patients with Hemophilia: is it safe?. <i>Journal of Cardiothoracic Surgery</i> , 2020, 15, 76.	0.4	12
454	Cross-cultural adaptation and validation of Haemophilia QoL in Cote d'Ivoire. <i>Haemophilia</i> , 2020, 26, 459-466.	1.0	4
455	Prophylaxis for hemophilia A without inhibitors: treatment options and considerations. <i>Expert Review of Hematology</i> , 2020, 13, 731-743.	1.0	16
456	Development of inhibitors in hemophilia A: An illustrated review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 752-760.	1.0	11
457	Hot topics in coagulation testing: Important considerations for testing children for bleeding/thrombotic disorders. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 68-74.	0.7	4
458	Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 446-454.	1.0	15
459	Cross-cultural adaptation and validation of the Canadian Hemophilia Outcomes-Kids™ Life Assessment Tool (CHO-KLAT) in Cote d'Ivoire (the Ivory Coast). <i>Health and Quality of Life Outcomes</i> , 2020, 18, 76.	1.0	4
460	High rate of SVR with DAA in haemophiliacs with HCV infection: Three decades of follow-up of a Portuguese single-centre cohort. <i>Liver International</i> , 2020, 40, 1783-1784.	1.9	3
461	FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1586-1597.	1.9	2
462	Hemophilia management: Huge impact of a tiny difference. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 377-385.	1.0	6
463	Hemostatic prophylaxis and colonoscopy outcomes for patients with bleeding disorders: A retrospective cohort study and review of the literature. <i>Haemophilia</i> , 2020, 26, 257-268.	1.0	4
464	Spontaneous subepithelial hemorrhage of renal pelvis and ureter (Antopol-Goldman lesion) in hemophilia A patient with inhibitor. <i>Medicine (United States)</i> , 2020, 99, e20851.	0.4	8
465	Generation of Functional Liver Sinusoidal Endothelial Cells from Human Pluripotent Stem-Cell-Derived Venous Angioblasts. <i>Cell Stem Cell</i> , 2020, 27, 254-269.e9.	5.2	50
466	Identification and functional characterization of a novel splicing variant in the F8 coagulation gene causing severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1050-1064.	1.9	2
467	Global coagulation assays in hemophilia A: A comparison to conventional assays. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 298-308.	1.0	12

#	ARTICLE	IF	CITATIONS
468	Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review. <i>European Journal of Haematology</i> , 2020, 104, 519-525.	1.1	15
469	A Closed-Tube Nested Quantitative PCR Assay for Rapid Detection of Intron 22 Inversions in the Factor VIII Gene. <i>Clinical Chemistry</i> , 2020, 66, 373-378.	1.5	0
470	Investigational drugs to treat hemophilia. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 295-301.	1.9	10
471	Discrepant Hemophilia A: An Underdiagnosed Disease Entity. <i>American Journal of Clinical Pathology</i> , 2020, 154, 78-87.	0.4	4
472	CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs. <i>Haematologica</i> , 2021, 106, 829-837.	1.7	19
473	Invasive procedures in patients with haemophilia: Review of low-dose protocols and experience with extended half-life FVIII and FIX concentrates and non-replacement therapies. <i>Haemophilia</i> , 2021, 27, 46-52.	1.0	18
474	Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 273-280.	0.7	7
475	Falsely decreased FVIII activity following pneumatic tube transport. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 305-310.	0.7	4
476	Risk factors for post-extraction bleeding in patients with haemophilia: a retrospective cohort study. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2021, 59, 341-346.	0.4	3
477	Genetics and Hemostatic Potential in Persons with Mild to Moderate Hemophilia A with a Discrepancy between One-Stage and Chromogenic FVIII Assays. <i>Thrombosis and Haemostasis</i> , 2021, 121, 027-035.	1.8	4
478	A Novel Assessment of Factor VIII Activity by Template Matching Utilizing Weighted Average Parameters from Comprehensive Clot Waveform Analysis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 164-173.	1.8	6
479	Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea. <i>Haemophilia</i> , 2021, 27, e12-e21.	1.0	10
480	Transient blood thinning during extracorporeal blood purification via the inactivation of coagulation factors by hydrogel microspheres. <i>Nature Biomedical Engineering</i> , 2021, 5, 1143-1156.	11.6	54
481	Advances in Recombinant Coagulation Factor VIII. <i>Pharmacy Information</i> , 2021, 10, 268-273.	0.1	0
482	Isokinetic knee strength deficit in patients with moderate haemophilia. <i>Haemophilia</i> , 2021, 27, 634-640.	1.0	5
484	The Function of extravascular coagulation factor IX in haemostasis. <i>Haemophilia</i> , 2021, 27, 332-339.	1.0	22
485	Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature. <i>TH Open</i> , 2021, 05, e183-e187.	0.7	3
486	First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China. <i>Medicine (United States)</i> , 2021, 100, e26077.	0.4	0

#	ARTICLE	IF	CITATIONS
487	Validation of the Spanish Version of the VERITAS-PRN Scale to Assess Adherence to on Demand Regimens in Patients with Hemophilia. Patient Preference and Adherence, 2021, Volume 15, 967-974.	0.8	0
488	Perspective â€œ The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. Blood Reviews, 2021, 50, 100849.	2.8	4
489	Hemophilic Arthropathy in Children: Pathophysiology, Diagnosis and Management. Duzce Universitesi Tip FakÃ¼ltesi Dergisi, 0, , .	0.3	0
490	Optimising prophylaxis in haemophilia A: The ups and downs of treatment. Blood Reviews, 2021, 50, 100852.	2.8	20
491	The Most Prominent Hemophilia Clotting Factors in the Province of Nineveh. Asian Journal of Pharmaceutical Research, 2021, , 85-91.	0.2	0
492	Characteristics of Haemophilia Patients: A One-Year Experience from A Tertiary Care Hospital in Bangladesh. Haematology Journal of Bangladesh, 2021, 5, 10-14.	0.1	1
493	Quality of life and its predictors among adult patients with haemophilic arthropathy. An observational study. BMC Musculoskeletal Disorders, 2021, 22, 448.	0.8	15
494	Bispecific antibodies for the treatment of hemophilia A. Expert Opinion on Biological Therapy, 2022, 22, 1029-1042.	1.4	2
495	Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients. Journal of Blood Medicine, 2021, Volume 12, 483-495.	0.7	1
496	Haemophilia. Nature Reviews Disease Primers, 2021, 7, 45.	18.1	103
497	Nonfactor Therapies: New Approaches to Prophylactic Treatment of Haemophilia. Hamostaseologie, 2021, 41, 247-256.	0.9	3
498	Musculoskeletal Changes in Hemophilia Patients Subsequent to COVID~19 Lockdown. Healthcare (Switzerland), 2021, 9, 702.	1.0	4
499	The spectrum of FVIII gene variants detected by next generation sequencing in 236 Chinese non-inversion hemophilia A pedigrees. Thrombosis Research, 2021, 202, 8-13.	0.8	4
500	Risk factors for antibody formation in children with hemophilia: methodological aspects and clinical characteristics of the HEMFIL cohort study. Blood Coagulation and Fibrinolysis, 2021, 32, 443-450.	0.5	2
501	Treatment~related risk factors for inhibitor development in non~severe hemophilia A after 50 cumulative exposure days: A case~control study. Journal of Thrombosis and Haemostasis, 2021, 19, 2171-2181.	1.9	8
502	Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. Expert Opinion on Biological Therapy, 2021, 21, 1165-1171.	1.4	3
503	Prospective study examining the use of thrombin~gelatin matrix (Flo seal) to prevent post dental extraction haemorrhage in patients with inherited bleeding disorders. International Journal of Oral and Maxillofacial Surgery, 2022, 51, 426-430.	0.7	4
504	Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood, 2021, 138, 2853-2873.	0.6	23

#	ARTICLE	IF	CITATIONS
505	Dissection of pleiotropic effects of variants in and adjacent to F8 exon 19 and rescue of mRNA splicing and protein function. <i>American Journal of Human Genetics</i> , 2021, 108, 1512-1525.	2.6	13
506	Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. <i>Thrombosis Research</i> , 2021, 205, 99-105.	0.8	4
507	Tratamiento de la hemofilia: de la terapia sustitutiva a la terapia génica. <i>Medicina Clínica</i> , 2021, 157, 583-587.	0.3	6
508	Complete characterisation of two new large Xq28 duplications involving <i>F8</i> using whole genome sequencing in patients without haemophilia A. <i>Haemophilia</i> , 2022, 28, 117-124.	1.0	4
509	Clinical Analysis of Hospitalized Patients with Hemophilia A: Single-hemophilia Treatment Center Experience in Korea over 10 years. <i>Blood Research</i> , 2021, 56, 141-149.	0.5	1
510	Perioperative haematological outcomes following total knee arthroplasty in haemophiliacs. <i>Journal of Orthopaedic Surgery</i> , 2021, 29, 230949902110339.	0.4	1
511	An anesthetic management of head and neck cancer reconstructive surgery in a patient having hemophilia A: a case report. <i>Journal of Dental Anesthesia and Pain Medicine</i> , 2021, 21, 261.	0.4	0
512	Platelet function and microvesicle generation in patients with hemophilia A. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 1408-1415.	0.2	1
513	A New Technology Standard for Safety and Efficacy in Factor VIII Replacement Therapy: Designing an Advanced Category rFVIII Concentrate. , 0, , 419-449.		6
514	Quality of Life in Hemophilia. , 2010, , 1895-1920.		25
515	Functionality and range of motion in patients with hemophilic ankle arthropathy treated with fascial therapy. A randomized clinical trial. <i>Musculoskeletal Science and Practice</i> , 2020, 49, 102194.	0.6	6
516	Utility of the Platelet Function Analyzer in Patients with Suspected Platelet Function Disorders: Diagnostic Accuracy Study. <i>TH Open</i> , 2020, 04, e427-e436.	0.7	3
517	Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases. <i>JCI Insight</i> , 2019, 4, .	2.3	28
518	Persons with Haemophilia in Sweden- Experiences and Strategies in Everyday Life. A Single Centre Study. <i>PLoS ONE</i> , 2015, 10, e0139690.	1.1	23
519	Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test “ Demonstrated in vitro and ex vivo. <i>PLoS ONE</i> , 2017, 12, e0175030.	1.1	3
520	Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. <i>PLoS ONE</i> , 2020, 15, e0240896.	1.1	9
521	Nurse-led telephone review service for mild inherited bleeding disorders improves attendance rates, frees hospital resources and is highly rated by patients. <i>The Journal of Haemophilia Practice</i> , 2018, 5, 66-75.	0.2	2
522	Noninvasive prenatal diagnosis of hemophilia A by a haplotype-based approach using cell-free fetal DNA. <i>BioTechniques</i> , 2020, 68, 117-121.	0.8	5

#	ARTICLE	IF	CITATIONS
523	æ—¥æœ-äººè;€â«ç—...Bæ,£è€...ã«è³ã,ã,%ã,CEãŸ18ç“é;žã®é³ã¼ãã%ãç•°. Japanese Journal of Thrombosis and Hemostasis, 2004, 15, 1		
524	2013 revised edition : hemostatic treatment guidelines for hemophilia patients without inhibitors. Japanese Journal of Thrombosis and Hemostasis, 2013, 24, 619-639.	0.1	11
525	2013 revised edition : hemostatic treatment guidelines for inhibitors possess congenital hemophilia patients. Japanese Journal of Thrombosis and Hemostasis, 2013, 24, 640-658.	0.1	7
526	Do Therapeutic Exercises Improve Kinesophobia and Health-Related Quality of Life in Adult Hemophilia Patients? A randomized controlled trial.. International Journal of Disabilities Sports & Health Sciences, 0, , 11-19.	0.3	2
527	Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea. Korean Journal of Pediatrics, 2013, 56, 291.	1.9	2
528	Hemophilic Arthropathy. Orthopedics, 2017, 40, e940-e946.	0.5	27
529	Hemophilic arthropathy: clinical, radiologic, and functional evaluation: a single-center experience in a limited resource country. Egyptian Rheumatology and Rehabilitation, 2016, 43, 35-40.	0.2	4
530	Treatment of Bleeding in Hemophilia. Journal of the Korean Medical Association, 2007, 50, 815.	0.1	5
531	Prevalence of hepatitis C virus infection and human immunodeficiency virus in a cohort of Egyptian hemophiliac children. Annals of Saudi Medicine, 2012, 32, 200-202.	0.5	11
532	Musculoskeletal Care of the Hemophiliac Patient. Journal of the American Academy of Orthopaedic Surgeons, The, 2012, 20, 553-563.	1.1	12
533	A survey of physiciansâ€™ treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries. Current Medical Research and Opinion, 2022, 38, 65-73.	0.9	8
534	Congenital hemophilia A with low activity of factor XII: a case report and literature review. Italian Journal of Pediatrics, 2021, 47, 204.	1.0	0
535	One Session Effects of Knee Motion Visualization Using Immersive Virtual Reality in Patients with Hemophilic Arthropathy. Journal of Clinical Medicine, 2021, 10, 4725.	1.0	3
536	A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran. Medicine (United States), 2021, 100, e27303.	0.4	2
537	Molecular Analysis of Hemophilia B: Â»Greifswald Registry FIX Deficiency (Hemophilia B)Â«. , 2003, , 35-48.		0
538	Angeborene plasmatische GerinnungsstÃ¶rungen. , 2003, , 1137-1152.		0
539	Diseases of the Blood. , 2006, , 745-779.		0
540	Diseases of the Blood. , 2006, , 745-779.		0

#	ARTICLE	IF	CITATIONS
541	Current use of bypassing agents in Japan in patients with congenital hemophilia and inhibitors. Japanese Journal of Thrombosis and Hemostasis, 2007, 18, 627-639.	0.1	0
542	2r1/4Žã,ãf3ãf'ãf"ã,ãf1/4ã;æœ%ã...^â ©æ€\$è;€ã*ç—...æ,£è€...ã«ã~3/4ãªã,æ¢è;€æ²»ç™,ã,¬ã,ãf%ãf ©ã,ãf³. Japanese Journal of Thrombosis and Hemostasis, 2007, 18, 627-639.	0.1	0
543	The patient at risk from thrombosis and bleeding disorders. Reproductive Medicine and Assisted Reproductive Techniques Series, 2008, , 121-136.	0.1	0
545	Bleeding Disorders. , 2010, , 584-589.		0
546	Genetic Risk Factors of Hemophilia A. Journal of Genetic Medicine, 2010, 7, 1-8.	0.1	0
547	HÄmatologische und immunologische Krankheiten. , 2011, , 217-245.		0
548	Rheumatologische Manifestation bei hereditären hÄmatologischen Erkrankungen. , 2012, , 507-510.		0
549	Inborn Defects of the Coagulative System. , 2012, , 73-84.		0
550	Hemostasis. , 2012, , 2083-2128.		0
551	A case report: Successful treatment of a patient with acquired hemophilia A using a combination of low-dose prednisolone and double filtration plasmapheresis. Nihon Toseki Igakkai Zasshi, 2013, 46, 1007-1013.	0.2	0
552	Third molar extraction during bypass therapy in a patient with hemophilia A inhibitor. Nihon Koku Geka Gakkai Zasshi, 2013, 59, 658-662.	0.0	0
553	Prolonged PTT. , 2014, , 57-70.		0
554	Dynamic understanding of blood clotting and advances in hemophilia practice. Japanese Journal of Thrombosis and Hemostasis, 2014, 25, 371-379.	0.1	3
555	Orthopaedic Management of the Haemophilias. , 2014, , 319-330.		0
556	The Challenges of Conducting Clinical Trials in Diseases with Small Target Populations. RSC Drug Discovery Series, 2014, , 53-79.	0.2	0
557	Health-related quality of life of partners of adults with haemophilia. The Journal of Haemophilia Practice, 2015, 2, 20-26.	0.2	0
558	Living with mild haemophilia and care after a bleed â€“ a qualitative study. The Journal of Haemophilia Practice, 2016, 3, 14-23.	0.2	2
559	The activity of factor VIII and IX of cord blood at mid-trimester in fetuses without hemophilia. Journal of Genetic Medicine, 2016, 13, 89-94.	0.1	0

#	ARTICLE	IF	CITATIONS
560	Hemostatic treatment of hemophilia with inhibitors. Japanese Journal of Thrombosis and Hemostasis, 2017, 28, 480-487.	0.1	0
561	Recent advance in hemophilia practice utilizing the comprehensive coagulation function evaluation. Japanese Journal of Thrombosis and Hemostasis, 2017, 28, 451-459.	0.1	4
562	CLINICAL PROFILE OF HAEMOPHILIA IN CHILDREN IN A TERTIARY CARE CENTRE. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 5775-5777.	0.1	1
563	Measurement of coagulation activity of patients with hemophilia using half-life extension coagulation factors. Japanese Journal of Thrombosis and Hemostasis, 2018, 29, 10-19.	0.1	1
564	Implantoprosthesis rehabilitation of a patient with severe form of hemophilia B: a case report. Acta Haematologica Polonica, 2018, 49, 33-36.	0.1	1
565	Recombinant factor VIIa and prothrombin complex concentrates to treat bleeding episodes in hemophilic patients with inhibitors: a Systematic Review. Hematology & Transfusion International Journal, 2018, 6, .	0.1	0
566	Hemofili A HastalarÄ±ndaki Diz Artropatisi ve Bilateral Total Diz Artroplastisi OranÄ±. Sakarya Medical Journal, 2019, 9, 506-512.	0.1	0
567	A bispecific antibody demonstrates limited measurability in routine coagulation assays. Blood Coagulation and Fibrinolysis, 2020, 31, 353-365.	0.5	4
568	<p>Convenience Comparison Study of Reconstitution Devices for the Blood Coagulation Factor VIII Products Rurioctocog Alfa Pegol and Antihemophilic Factor (Recombinant)</p>. International Journal of General Medicine, 2020, Volume 13, 1469-1476.	0.8	0
569	An aberrant <i>F</i>8 intron 1 inversion with concomitant large duplication and deletion in a Chinese severe hemophilia A patient. Hematology, 2021, 26, 53-57.	0.7	1
570	Hemophilia A and Inhibitors. , 2008, , 389-405.		0
571	Peri-operative and Post-operative Management of Hemophilic Patients with Inhibitors. , 2008, , 51-55.		0
572	Case Study: Immunogenicity of Factor VIII. , 2008, , 147-171.		1
574	Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan. Thrombosis and Haemostasis, 2021, 121, 603-615.	1.8	7
575	Treatment of haemophilia: From replacement to gene therapy. Medicina ClÄnica (English Edition), 2021, 157, 583-587.	0.1	4
576	Acute coronay syndrome in a patient with severe hemophilia A: Dificult decisions. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 985.e1-985.e5.	0.2	1
577	SÄndrome coronÄria aguda em doente com hemofilia A grave: decisÃµes difÃceis. Revista Portuguesa De Cardiologia, 2021, 40, 985.e1-985.e1.	0.2	0
578	Etranacogene dezaparvovec for hemophilia B gene therapy. Therapeutic Advances in Rare Disease, 2021, 2, 263300402110588.	0.3	3

#	ARTICLE	IF	CITATIONS
579	Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients. <i>Journal of Pharmacopuncture</i> , 2018, 21, 76-81.	0.4	1
580	Two case of hemophilia carriers treated with coagulation factor VIII/IX. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 731-736.	0.1	0
581	Hemophilia Patient Experience in a Physical Therapy-Guided Health Education Intervention: A Mixed-Method Design. <i>Healthcare (Switzerland)</i> , 2021, 9, 1728.	1.0	0
582	Validity of the fourâ€square step test in persons with haemophilia. <i>Haemophilia</i> , 2022, 28, 334-342.	1.0	1
583	Effect of a fascial therapy treatment on quality of life in patients with hemophilic elbow arthropathy: a randomized controlled trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2022, , .	0.5	3
584	Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients. <i>International Journal of Hematology</i> , 2022, 115, 489-498.	0.7	12
585	International consensus recommendations on the management of people with haemophilia B. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210852.	1.1	13
586	The Molecular Basis of FIX Deficiency in Hemophilia B. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2762.	1.8	16
587	Resource utilization and treatment costs of patients with severe hemophilia A: Realâ€world data from the ATHNdataset. <i>EJHaem</i> , 2022, 3, 341-352.	0.4	4
588	Joint status of patients with nonsevere hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1126-1137.	1.9	17
589	BAFF rs9514828 gene polymorphism and the risk of the development of inhibitors in children with severe haemophilia A. <i>Haemophilia</i> , 2022, 28, 472-479.	1.0	1
590	Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice. <i>Frontiers in Genome Editing</i> , 2022, 4, 785698.	2.7	8
591	Therapeutic correction of hemophilia A by transplantation of hPSC-derived liver sinusoidal endothelial cell progenitors. <i>Cell Reports</i> , 2022, 39, 110621.	2.9	9
592	Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO.REC Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 1969.	1.0	6
593	Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A. <i>Current Medical Research and Opinion</i> , 2022, 38, 1133-1139.	0.9	1
594	Recurrent bleeding after rubber band ligation diagnosed as mild hemophilia B: a case report and literature review. <i>BMC Surgery</i> , 2022, 22, 124.	0.6	0
595	Effects of 14 <i>F9</i> synonymous codon variants on hemophilia B expression: Alteration of splicing along with protein expression. <i>Human Mutation</i> , 2022, 43, 928-939.	1.1	4
596	Unveiling the influence of factor VIII physicochemical properties on hemophilia A phenotype through an in silico methodology. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 219, 106768.	2.6	2

#	ARTICLE	IF	CITATIONS
597	Bleeding disorders in implant dentistry: a narrative review and a treatment guide. <i>International Journal of Implant Dentistry</i> , 2022, 8, 20.	1.1	7
598	Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates. <i>Haemophilia</i> , 2022, , .	1.0	3
599	Bleeding in the Neonate. , 0, , 643-671.		0
601	Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy. <i>International Journal of Hematology</i> , 2022, , .	0.7	1
602	Liver gene therapy with intein-mediated F8 <i>trans</i> splicing corrects mouse haemophilia A. <i>EMBO Molecular Medicine</i> , 2022, 14, e15199.	3.3	5
603	Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022. <i>Haemophilia</i> , 2022, 28, 93-102.	1.0	7
604	Prolonged $\pm$ -thrombin-related activation and delayed active protein C-associated degradation confer mild phenotype in a patient with severe hemophilia A with F8 p.H118R. <i>International Journal of Hematology</i> , 2022, , .	0.7	1
605	Screening of behavioral disorders in children with hemophilia. <i>International Journal of Rheumatic Diseases</i> , 0, , .	0.9	0
606	A Machine Learning Framework Predicts the Clinical Severity of Hemophilia B Caused by Point-Mutations. <i>Frontiers in Bioinformatics</i> , 0, 2, .	1.0	4
607	A pilot study assessing the implementation of 96-well plate-based aggregometry (Optimul) in Australia. <i>Pathology</i> , 2022, 54, 746-754.	0.3	2
608	Gait Alteration Due to Haemophilic Arthropathies in Patients with Moderate Haemophilia. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7527.	1.2	1
609	Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice. <i>Journal of Clinical Medicine</i> , 2022, 11, 3345.	1.0	2
610	Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	2
611	A Comparatively Study of Machine Learning Approaches to Predict Service of Disease Haemophilia A. , 2021, , .		0
612	Hemophilia in the south of Tunisia. <i>Blood Coagulation and Fibrinolysis</i> , 0, Publish Ahead of Print, .	0.5	0
613	Current and future therapies for haemophiliaâ€”Beyond factor replacement therapies. <i>British Journal of Haematology</i> , 2023, 200, 23-34.	1.2	19
614	Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	5
615	Activated partial thromboplastin time-based clot waveform analysis enables measurement of very low levels of factor IX activity in patients with severe hemophilia B. <i>International Journal of Hematology</i> , 0, , .	0.7	1

#	ARTICLE	IF	CITATIONS
616	Management of haemophilia A with inhibitors: A regional cross-talk. <i>Haemophilia</i> , 2022, 28, 950-961.	1.0	6
617	Prevalence of cardiovascular diseases and risk factors in adult patients with haemophilia: a cross-sectional study in a tertiary care hospital clinic in Sri Lanka. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	0.7	3
618	Hematuria in Patients with Congenital Coagulation Factor Deficiencies. <i>Journal of Dr Behcet Uz Children S Hospital</i> , 2022, 12, 191-196.	0.1	0
619	Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy. <i>Blood Reviews</i> , 2022, , 101011.	2.8	3
620	Comprehensive analysis of <i>F8</i> large deletions: Characterization of full breakpoint junctions and description of a possible DNA breakage hotspot in intron 6. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	1.9	4
621	The von Willebrand factor-binding aptamer ronocept as a treatment for severe and nonsevere hemophilia A. <i>Blood</i> , 2023, 141, 1147-1158.	0.6	3
622	Is Antifibrinolytic Therapy Effective for Preventing Hemorrhage in Patients with Hemophilia Undergoing Dental Extractions? A Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211148.	0.7	1
623	Outcome of Joint Aspiration in Acute Knee Haemarthrosis in a Haemophilic Joint: A Prospective Randomised Controlled Trial in 120 Patients in a Tertiary Haemophilia Care Centre. <i>Indian Journal of Orthopaedics</i> , 0, , .	0.5	0
624	Clot Waveform Analysis for Monitoring Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	1.5	5
625	The value of radiosynoviorthesis for treatment of chronic synovitis in haemophilic joint disease. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	0.4	0
626	Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A. <i>Haemophilia</i> , 2023, 29, 90-99.	1.0	8
627	Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature. <i>Haemophilia</i> , 2023, 29, 33-44.	1.0	4
628	Development of simple and rapid method for Emicizumab quantification by LC-MS/MS in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 223, 115163.	1.4	2
629	Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients. <i>Haemophilia</i> , 2023, 29, 156-164.	1.0	2
630	A Novel Deletion Mutation of the F8 Gene for Hemophilia A. <i>Diagnostics</i> , 2022, 12, 2876.	1.3	2
631	Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. <i>Blood Advances</i> , 2023, 7, 5671-5679.	2.5	16
632	Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 609-620.	1.5	8
633	Development of a target product profile (TPP) for haemophilia point-of-care (POC) diagnostic devices for low-resource countries and remote settings. <i>Haemophilia</i> , 2023, 29, 671-673.	1.0	1

#	ARTICLE	IF	CITATIONS
634	â€œiPSC-derived liver organoids and inherited bleeding disorders: Potential and future perspectivesâ€œ. <i>Frontiers in Physiology</i> , 0, 14, .	1.3	0
635	Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 546-552.	1.9	10
636	F8/F9 variants in the population-based PedNet Registry cohort compared with locus-specific genetic databases of the European Association for Haemophilia and Allied Disorders and the Centers for Disease Control and Prevention Hemophilia A or Hemophilia B Mutation Project. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100036.	1.0	1
637	Spectrum of Causative Mutations in Patients with Hemophilia A in Russia. <i>Genes</i> , 2023, 14, 260.	1.0	0
638	TRAUMA NA PRIMEIRA INFÃNCIA E O DIAGNÃSTICO DE HEMOFILIA: RELATO DE CASO. <i>Revista Foco</i> , 2023, 16, e851.	0.1	0
639	Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs. <i>Journal of Clinical Medicine</i> , 2023, 12, 1368.	1.0	1
640	Healthâ€related quality of life in persons with haemophilia in Afghanistan. <i>Haemophilia</i> , 2023, 29, 770-775.	1.0	0
641	Treatment changes in hemophilia A with chromogenic factor VIII assay implementation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100098.	1.0	0
642	Successful Multidisciplinary Management of Aortic Valve Repair in Severe Hemophilia B with Extended Half-Life Recombinant Factor IX concentrate. <i>Acta Haematologica</i> , 0, , .	0.7	0
643	EriÅŸkin Hemofili A ve Hemofili B HastalarÃ±n Klinik ve Laboratuvar DeÅŸerlendirilmesi Tek Merkez Deneyimi. <i>Dicle Medical Journal</i> , 0, , 96-101.	0.2	0
644	Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 239-252.	0.4	0
645	Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1737-1740.	1.9	5
646	Poor correlation between biomarkers and MRI-detected joint damage in a cross-sectional study of persons with nonsevere hemophilia A (DYNAMO study). <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1813-1823.	1.9	1
663	Laparoscopic hepatectomy for hepatocellular carcinoma in patients with hemophilia A and B: a report of two cases. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
671	Hemophilia B: Diagnosis and Management. , 2023, , 145-171.		0
672	Hemophilia A: Diagnosis and Management. , 2023, , 107-143.		0